Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · IEX Real-Time Price · USD
51.30
-0.72 (-1.38%)
At close: Jul 2, 2024, 4:00 PM
51.29
-0.01 (-0.02%)
After-hours: Jul 2, 2024, 5:50 PM EDT
Halozyme Therapeutics Employees
Halozyme Therapeutics had 373 employees as of December 31, 2023. The number of employees decreased by 20 or -5.09% compared to the previous year.
Employees
373
Change (1Y)
-20
Growth (1Y)
-5.09%
Revenue / Employee
$2,313,643
Profits / Employee
$854,697
Market Cap
6.53B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 373 | -20 | -5.09% |
Dec 31, 2022 | 393 | 248 | 171.03% |
Dec 31, 2021 | 145 | 9 | 6.62% |
Dec 31, 2020 | 136 | 4 | 3.03% |
Dec 31, 2019 | 132 | -149 | -53.02% |
Dec 31, 2018 | 281 | 26 | 10.20% |
Dec 31, 2017 | 255 | -4 | -1.54% |
Dec 31, 2016 | 259 | 43 | 19.91% |
Dec 31, 2015 | 216 | 63 | 41.18% |
Dec 31, 2014 | 153 | -17 | -10.00% |
Dec 31, 2013 | 170 | 18 | 11.84% |
Dec 31, 2012 | 152 | 17 | 12.59% |
Dec 31, 2011 | 135 | 33 | 32.35% |
Dec 31, 2010 | 102 | -38 | -27.14% |
Dec 31, 2009 | 140 | 10 | 7.69% |
Dec 31, 2008 | 130 | 38 | 41.30% |
Dec 31, 2007 | 92 | 52 | 130.00% |
Dec 31, 2006 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Acadia Healthcare Company | 23,500 |
Penumbra | 4,200 |
Masimo | 3,800 |
Jazz Pharmaceuticals | 2,800 |
Repligen | 1,783 |
Exelixis | 1,310 |
Ionis Pharmaceuticals | 927 |
Blueprint Medicines | 655 |
HALO News
- 8 days ago - Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis - PRNewsWire
- 11 days ago - Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy - PRNewsWire
- 26 days ago - Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook - PRNewsWire
- 27 days ago - Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform - PRNewsWire
- 4 weeks ago - Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - PRNewsWire
- 6 weeks ago - Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE® - PRNewsWire
- 7 weeks ago - Halozyme to Participate in Upcoming Investor Conferences - PRNewsWire
- 2 months ago - HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS - PRNewsWire